Evaxion Biotech A/S

EVAX54

Penny Stock

$3.40arrow_drop_up13.33%$0.40

Penny Stock

EVAX54

$3.40

arrow_drop_up13.33%$0.40

Penny Stock

Performance History

Key Stats
Open	$3.11
Prev. Close	$3.06
EPS	-4.50
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$16.72M
PE Ratio	-

	LOW	HIGH
Day Range	2.80	3.17
52 Week Range	2.26	13.61

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-4.50

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Evaxion Biotech A/S (EVAX)

Evaxion Biotech A/S (EVAX) is a renowned biotechnology company specializing in the development of novel immunotherapies for the treatment of cancer and infectious diseases. With a firm commitment to scientific innovation, Evaxion is at the forefront of utilizing cutting-edge artificial intelligence and machine learning technologies to identify and evaluate potential therapeutic targets.

As of the latest update, the stock price of EVAX is not available. For the most up-to-date information, please refer to a reliable financial news source or consult your financial advisor.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO
Headquarters: Horsholm
Employees: 63
Exchange: NASDAQ

Keep an eye on Evaxion Biotech A/S

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Evaxion Biotech A/S's (EVAX) price per share?

The current price per share for Evaxion Biotech A/S (EVAX) is $3.4. The stock has seen a price change of $0.4 recently, indicating a 13.33% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Evaxion Biotech A/S (EVAX)?

For Evaxion Biotech A/S (EVAX), the 52-week high is $13.61, which is 300.29% from the current price. The 52-week low is $2.26, the current price is 50.44% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Evaxion Biotech A/S (EVAX) a growth stock?

Evaxion Biotech A/S (EVAX) has shown an average price growth of 0.41% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Evaxion Biotech A/S as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Evaxion Biotech A/S (EVAX) stock price performance year to date (YTD)?

As of the latest data, Evaxion Biotech A/S (EVAX) has a year-to-date price change of -53.42%. Over the past month, the stock has experienced a price change of 12.4%. Over the last three months, the change has been 37.65%. Over the past six months, the figure is 13.71%.

help

Is Evaxion Biotech A/S (EVAX) a profitable company?

Evaxion Biotech A/S (EVAX) has a net income of -$22.16M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.97K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $73.11K. Operating income is noted at -$22.23M. Furthermore, the EBITDA is -$18.8M.

help

What is the market capitalization of Evaxion Biotech A/S (EVAX)?

Evaxion Biotech A/S (EVAX) has a market capitalization of $16.73M. The average daily trading volume is 70.07K, indicating the stock's liquidity and investor engagement.

News

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

HEALTH

6/26/2024

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

HEALTH

CLINICAL STUDY

6/17/2024

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal